Literature DB >> 25941610

Th1 epitope selection for clinically effective cancer vaccines.

Mary L Disis1, William C Watt1, Denise L Cecil1.   

Abstract

New cancer immunotherapies mark progress in our understanding of tumor biology and harnessing the immune system's management of self. However, protein- and peptide-based vaccines are not yet consistently efficacious. Recent work uncovers principles governing the genesis of T helper type-restrictive immunity to self-antigens elicited by vaccine epitopes, enabling vaccines to skew the balance from tolerogenic Type II (Th2) to inflammatory Type I (Th1) T cells, and invigorating this cancer immunotherapeutic approach.

Entities:  

Keywords:  Helper T-cells; IGFBP-2; Th1; Th2; epitope

Year:  2014        PMID： 25941610      PMCID： PMC4292222          DOI： 10.4161/21624011.2014.954971

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  9 in total

1.  Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature.

Authors:  Margaret Inokuma; Corazon dela Rosa; Charles Schmitt; Perry Haaland; Janet Siebert; Douglas Petry; Mengxiang Tang; Maria A Suni; Smita A Ghanekar; Daiva Gladding; John F Dunne; Vernon C Maino; Mary L Disis; Holden T Maecker
Journal:  J Immunol       Date:  2007-08-15       Impact factor: 5.422

Review 2.  Key roles of adjuvants in modern vaccines.

Authors:  Steven G Reed; Mark T Orr; Christopher B Fox
Journal:  Nat Med       Date:  2013-12-05       Impact factor: 53.440

3.  Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity.

Authors:  Denise L Cecil; Gregory E Holt; Kyong Hwa Park; Ekram Gad; Lauren Rastetter; Jennifer Childs; Doreen Higgins; Mary L Disis
Journal:  Cancer Res       Date:  2014-04-28       Impact factor: 12.701

4.  Characterization of antigen-specific immune responses induced by canarypox virus vaccines.

Authors:  Rinke Bos; Suzanne van Duikeren; Thorbald van Hall; Marjolein M Lauwen; Mark Parrington; Neil L Berinstein; Bryan McNeil; Cornelis J M Melief; J Sjef Verbeek; Sjoerd H van der Burg; Rienk Offringa
Journal:  J Immunol       Date:  2007-11-01       Impact factor: 5.422

5.  Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer.

Authors:  Kyong Hwa Park; Ekram Gad; Vivian Goodell; Yushe Dang; Thayer Wild; Doreen Higgins; Patty Fintak; Jennifer Childs; Corazon Dela Rosa; Mary L Disis
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

6.  TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma.

Authors:  Emmanuella Guenova; Rei Watanabe; Jessica E Teague; Jennifer A Desimone; Ying Jiang; Mitra Dowlatshahi; Christoph Schlapbach; Knut Schaekel; Alain H Rook; Marianne Tawa; David C Fisher; Thomas S Kupper; Rachael A Clark
Journal:  Clin Cancer Res       Date:  2013-06-19       Impact factor: 12.531

7.  CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer.

Authors:  Shuzhen Liu; Jonathan Lachapelle; Samuel Leung; Dongxia Gao; William D Foulkes; Torsten O Nielsen
Journal:  Breast Cancer Res       Date:  2012-03-15       Impact factor: 6.466

8.  Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation.

Authors:  Alexander Pedroza-Gonzalez; Kangling Xu; Te-Chia Wu; Caroline Aspord; Sasha Tindle; Florentina Marches; Michael Gallegos; Elizabeth C Burton; Daniel Savino; Toshiyuki Hori; Yuetsu Tanaka; Sandra Zurawski; Gerard Zurawski; Laura Bover; Yong-Jun Liu; Jacques Banchereau; A Karolina Palucka
Journal:  J Exp Med       Date:  2011-02-21       Impact factor: 14.307

9.  A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma.

Authors:  Lisa M Ebert; Sarah E MacRaild; Damien Zanker; Ian D Davis; Jonathan Cebon; Weisan Chen
Journal:  PLoS One       Date:  2012-10-26       Impact factor: 3.240
  9 in total
  5 in total

Review 1.  B cells, plasma cells and antibody repertoires in the tumour microenvironment.

Authors:  George V Sharonov; Ekaterina O Serebrovskaya; Diana V Yuzhakova; Olga V Britanova; Dmitriy M Chudakov
Journal:  Nat Rev Immunol       Date:  2020-01-27       Impact factor: 53.106

2.  Moving forward with human papillomavirus immunotherapies.

Authors:  Nicolas Çuburu; John T Schiller
Journal:  Hum Vaccin Immunother       Date:  2016-07-07       Impact factor: 3.452

3.  Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patients.

Authors:  Caroline Laheurte; Jeanne Galaine; Laurent Beziaud; Magalie Dosset; Jerome Kerzerho; Claire Jacquemard; Béatrice Gaugler; Christophe Ferrand; Anne Dormoy; François Aubin; Pascale Jacoulet; Virginie Westeel; Christophe Borg; Eric Tartour; Yann Godet; Bernard Maillère; Olivier Adotévi
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

4.  Noncutaneous and Cutaneous Cancer Risk in Patients With Atopic Dermatitis: A Systematic Review and Meta-analysis.

Authors:  Lily Wang; Rachel Bierbrier; Aaron M Drucker; An-Wen Chan
Journal:  JAMA Dermatol       Date:  2020-02-01       Impact factor: 10.282

5.  Cationic domains in particle-forming and assembly-deficient HBV core antigens capture mammalian RNA that stimulates Th1-biased antibody responses by DNA vaccination.

Authors:  Jana Krieger; Katja Stifter; Petra Riedl; Reinhold Schirmbeck
Journal:  Sci Rep       Date:  2018-10-02       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.